Resveratrol as a Preventive Treatment of OHSS

IVI Madrid70 enrolled

Overview

Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors

Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Infertility

Interventions

ResveratrolDRUG

Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

PlaceboDRUG

Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Number of follicles greater than 12 mm after ovarian stimulation * Number of retrieved oocytes greater than 21 Exclusion Criteria: * \>35 years-old * PCOS * Endometriosis * Systemic pathology * Positive serologies for HBV, HBC and HIV * Abnormal karyotype

Locations (1)

Ivi Madrid

Madrid, Spain

Outcomes

Primary Outcomes

Serum VEGF levels

Serum determination of VEGF levels

Time frame: 1 day

Secondary Outcomes

Hemoconcentration

Volume of red blood cells measured in percentage

Time frame: 1 day

Serum estradiol levels

Serum determination of estradiol levels asessed in picograms per mililiter

Time frame: 1 day

Ascitis

Volume of liquid in Douglas pouch asessed in mililiters

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.